PAP TEST: AVERAGE-RISK AND HIGH-RISK WOMEN

INCREASE IN LIFE EXPECTANCY (days)

INCREASE IN TOTAL COSTS (dollars)

FREQUENCY OF PAP TEST (NUMBER OF YEARS BETWEEN TESTS)
New production methods now make it possible for Pfanstiehl Laboratories to offer Daunosamine in commercial quantities in the form of Methyl-L-daunosamine-hydrochloride. It will be available in gram and multi-gram quantities.

Daunosamine is a vital component of Doxorubicin, Adriamycin and other active antineoplastic compounds and, until now, has been produced only in extremely limited amounts. Broader availability will permit intensified research with these promising anti-cancer agents.

Several other Pfanstiehl biochemicals also are being used in cancer and anti-viral research, among them: 5-Thio-D-Glucose, 2-Deoxy-D-Glucose, and Ara-A (9-β-D-Arabinofuranosyl-adenine). We invite your inquiry.

Use coupon below to request technical literature and obtain our current catalog.

PFANSTIEHL LABORATORIES, INC.
1219 Glen Rock Ave. • Waukegan, IL 60085
Tel: (312) 623-0370

Please send me literature on:

☐ Daunosamine ☐ 5-Thio-D-Glucose
☐ 2-Deoxy-D-Glucose ☐ Ara-A
☐ Latest Pfanstiehl Catalog 20-J

Please use this coupon and attach a recent label in the space provided when writing to us about:

- change of address
- renewal
- questions regarding your subscription

Please use the space below to indicate your new address.

Name of Journal ______________________
Name ______________________________
Address ____________________________
City ________________________________
State/Zip __________________________

The Williams & Wilkins Co.
428 East Preston Street
Baltimore, Maryland 21202
Cancer and its consequences can be prevented in two main ways: primary and secondary prevention. Primary prevention is achieved through identifying and eliminating carcinogenic hazards, such as tobacco. Secondary prevention attempts to detect and treat cancers or its precursors when they are in early stages and are more curable. The seven warning signals of the American Cancer Society, for example, were designed to help people detect cancers in early stages. The periodic examination of asymptomatic persons with tests such as the Papanicolaou (Pap) test and sigmoidoscopy can potentially detect cancers even before the development of signs or symptoms.

In 1979, Dr. David M. Eddy, M.D., Ph.D., then at Stanford University, now the Director of the Center for the Study of Health Policy at Duke University, provided a theoretical basis for helping clinicians and health planners decide how they can most effectively screen for cancer: which tests should be used, on what patients, and how frequently? His theory is described in the book, Screening for Cancer: Theory, Analysis and Design (Prentice-Hall, Inc., 1980). It enables decision-makers to estimate the risks and the effectiveness, as well as the costs, of screening with different tests in different circumstances.

On the basis of the work of Dr. Eddy and others, the American Cancer Society revised several of its recommendations concerning the cancer-related health checkup. The major changes are: that women over the age of 20 and women under 20 who are sexually active should have a Pap test at least every 3 years after two initial negative tests a year apart; and that men and women over the age of 50 should have a stool guaiac slide test annually, and a sigmoidoscopical examination every 3 to 5 years after two initial negative examinations a year apart. At this time the American Cancer Society does not believe that there is sufficient evidence of benefit to justify a broad recommendation that asymptomatic people, even smokers, have a chest X-ray.

The diagram on the cover is taken from Dr. Eddy's book. It illustrates some of the medical and financial consequences of screening a woman, from age 20 on, with a Pap test at various frequencies. It compares the improvement in life expectancy an asymptomatic woman can expect to gain with Pap test examinations, with the increase in the financial costs. The results are shown for high-risk women and for average-risk women.

Dr. Eddy received his medical degree from the University of Virginia and did an internship and 2 years of residency in surgery at Stanford University. Later he received a Ph.D. in engineering at Stanford University. He has been a consultant to many organizations including the American Cancer Society, the National Cancer Institute, the Congressional Office of Technology Assessment, the National Center for Health Care Technology, the American Joint Committee on Cancer Staging, the National Commission on Digestive Diseases, and the Blue Cross/Blue Shield Association.

M.B.S.